RX πŸ“ˆ Biosyent - Overview

Exchange: V • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA0906901081

RX: Pharmaceuticals, Supplements, Hormones, Lubricants, Suppositories, Gels

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada. Web URL: https://www.biosyent.com

Additional Sources for RX Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

RX Stock Overview

Market Cap in USD 87m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception

RX Stock Ratings

Growth 5y 66.7%
Fundamental 59.9%
Dividend 61.1%
Rel. Strength Industry 1032
Analysts -
Fair Price Momentum 11.95 CAD
Fair Price DCF 0.68 CAD

RX Dividends

Dividend Yield 12m 1.61%
Yield on Cost 5y 3.12%
Annual Growth 5y 65.10%
Payout Consistency 100.0%

RX Growth Ratios

Growth Correlation 3m 47.8%
Growth Correlation 12m 94%
Growth Correlation 5y 78.2%
CAGR 5y 13.25%
CAGR/Mean DD 5y 0.93
Sharpe Ratio 12m 0.89
Alpha 14.88
Beta 0.47
Volatility 28.15%
Current Volume 5.2k
Average Volume 20d 3.2k
What is the price of RX stocks?
As of January 15, 2025, the stock is trading at CAD 10.86 with a total of 5,180 shares traded.
Over the past week, the price has changed by +0.18%, over one month by -6.51%, over three months by +4.30% and over the past year by +32.64%.
Is Biosyent a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Biosyent (V:RX) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 59.88 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RX as of January 2025 is 11.95. This means that RX is currently undervalued and has a potential upside of +10.04% (Margin of Safety).
Is RX a buy, sell or hold?
Biosyent has no consensus analysts rating.
What are the forecast for RX stock price target?
According to ValueRays Forecast Model, RX Biosyent will be worth about 13.1 in January 2026. The stock is currently trading at 10.86. This means that the stock has a potential upside of +20.26%.
Issuer Forecast Upside
Wallstreet Target Price 11.8 8.2%
Analysts Target Price - -
ValueRay Target Price 13.1 20.3%